Canine liver transplantation under nva cyclosporine versus cyclosporine

Satoru Todo, Kendrick A. Porter, Igal Kam, Stephen Lynch, Raman Venkataramanan, Andre DeWolf, Thomas E. Starzl*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


The immunosuppressive qualities and other features of a new cyclosporine (CsA) analogue, Nva 2-cyclosporine (Nva 2-CsA) were examined using canine orthotopic liver allografts. The mean survival time was 11.8±9.6 (SD) days in dogs without treatment, 60.8±34.4 days with Nva 2-CsA and 65.1±33.0 days with CsA. Functional abnormalities indicating toxic side effects were not noted either with Nva 2-CsA or with CsA. Using the same oral dose, the rate of blood level rise and the amount of the rise were greater with Nva2-CsA. Histopathologically, Nva2-CsA the treatment was associated with the same degree of hydropic vocuolation in the pars recta of the proximal tubules as CsA treatment. Thus, in the dog, Nva2-CsA had identical immunosuppressive properties as CsA, with no functionally detectable toxicity affecting the liver and kidney.

Original languageEnglish (US)
Pages (from-to)296-300
Number of pages5
Issue number3
StatePublished - Mar 1986

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Canine liver transplantation under nva cyclosporine versus cyclosporine'. Together they form a unique fingerprint.

Cite this